Predicting neoadjuvant chemotherapy treatment response in hormone-receptor-positive/HER2-negative breast cancer – results from the Swedish SCAN-B population-based cohort
Background and purpose: Hormone-receptor-positive/HER2-negative (HR+/HER2-) early-stage breast cancers (EBCs) display heterogenous responses to neoadjuvant chemotherapy (NACT) warranting biomarkers to tailor optimal treatment for individual patients. Patients/material and methods: Women with HR+/HER2-EBC (N = 178) included in the Swedish Sweden Cancerome Analysis Network-Breast (SCAN-B) population
